http://www.wikiweed.com/index.php?action=history&feed=atom&title=ADB-FUBINACA 2026-04-28T19:40:34Z Revision history for this page on the wiki MediaWiki 1.24.1 http://www.wikiweed.com/index.php?title=ADB-FUBINACA&diff=3243&oldid=prev 2015-04-14T11:33:51Z

<p></p> <table class='diff diff-contentalign-left'> <col class='diff-marker' /> <col class='diff-content' /> <col class='diff-marker' /> <col class='diff-content' /> <tr style='vertical-align: top;'> <td colspan='2' style="background-color: white; color:black; text-align: center;">← Older revision</td> <td colspan='2' style="background-color: white; color:black; text-align: center;">Revision as of 11:33, 14 April 2015</td> </tr><tr><td colspan="2" class="diff-lineno">Line 1:</td> <td colspan="2" class="diff-lineno">Line 1:</td></tr> <tr><td class='diff-marker'>−</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>'''ADB-FUBINACA''' is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982, with a Ki value of 0.36nM at CB1. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like [[SDB-001]] and[[ STS-135]]. ADB-FUBINACA appears to be the product of rational drug design, since it differs from [[AB-FUBINACA]] only by the replacement of the isopropyl group with a tert-butyl group. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved. Nothing is known of the pharmacological activity of ADB-FUBINACA in humans or other animals.</div></td><td class='diff-marker'>+</td><td style="color:black; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>'''ADB-FUBINACA''' is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982, with a Ki value of 0.36nM at CB1. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like [[SDB-001]] and[[<ins class="diffchange diffchange-inline">STS-135 (drug)|</ins>STS-135]]. ADB-FUBINACA appears to be the product of rational drug design, since it differs from [[AB-FUBINACA]] only by the replacement of the isopropyl group with a tert-butyl group. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved. Nothing is known of the pharmacological activity of ADB-FUBINACA in humans or other animals.</div></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"></td></tr> <tr><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==See also==</div></td><td class='diff-marker'>&#160;</td><td style="background-color: #f9f9f9; color: #333333; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #e6e6e6; vertical-align: top; white-space: pre-wrap;"><div>==See also==</div></td></tr> </table>

Adm1n http://www.wikiweed.com/index.php?title=ADB-FUBINACA&diff=1322&oldid=prev 2015-02-15T02:27:05Z

<p>Created page with &quot;&#039;&#039;&#039;ADB-FUBINACA&#039;&#039;&#039; is a designer drug identified in <a href="/Synthetic_cannabis" title="Synthetic cannabis">synthetic cannabis</a> blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/1069...&quot;</p> <p><b>New page</b></p><div>'''ADB-FUBINACA''' is a designer drug identified in [[synthetic cannabis]] blends in Japan in 2013. The (S) enantiomer of ADB-FUBINACA is claimed in Pfizer patent WO 2009/106982, with a Ki value of 0.36nM at CB1. ADB-FUBINACA features a carboxamide group at the 3-indazole position, like [[SDB-001]] and[[ STS-135]]. ADB-FUBINACA appears to be the product of rational drug design, since it differs from [[AB-FUBINACA]] only by the replacement of the isopropyl group with a tert-butyl group. The stereochemistry of the tert-butyl side-chain in the illicitly sold product is unresolved. Nothing is known of the pharmacological activity of ADB-FUBINACA in humans or other animals.<br /> <br /> ==See also==<br /> * [[AB-FUBINACA]]<br /> * [[ADB-PINACA]]<br /> * [[ADBICA]]<br /> * [[APINACA]]<br /> * [[PF-03550096]]<br /> * [[SDB-001]]<br /> * [[STS-135 (drug)|STS-135]]</div>

Adm1n